Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. - Wikidata - awgldk - TriplyDB

Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis.

Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis.

http://www.wikidata.org/entity/Q48382207

about

Update on treatment of light chain amyloidosis Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study Exploring Big Data in Hematological Malignancies: Challenges and Opportunities.Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis.Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.Pathophysiology and treatment of systemic amyloidosis.Immunoglobulin light chain amyloidosis.Pathophysiology and treatment of cardiac amyloidosis.Natural history and therapy of AL cardiac amyloidosis.Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity.Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.Emerging Advances in the Management of Cardiac Amyloidosis.Recent advances in the management of AL Amyloidosis.Novel strategies for the diagnosis and treatment of cardiac amyloidosis.New and developing therapies for AL amyloidosis.Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.A Case of Cardiac Light Chain Deposition Disease in a Patient with Solitary Plasmacytoma.Prognostic implication of relative regional strain ratio in cardiac amyloidosis.Light chain amyloidosis: the heart of the problem.Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting.Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP.Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up.Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement.Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis.Dysproteinemias and Glomerular Disease.New concepts in the treatment and diagnosis of amyloidosis.Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.Amyloid in bone marrow smears in systemic light-chain amyloidosis.Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009.Light Chain Amyloidosis.Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.Novel Therapies in Light Chain Amyloidosis.

P2860

Q26829735-F2F9236C-2C53-410E-8EAF-E6BD1089C8AB Q30278687-80CACCF2-3755-416D-B14D-86CA09B97796 Q31095966-5C41C929-2F89-44FD-A26A-0C443C1E948B Q34448455-EE8D807F-4CD9-40F5-8F1C-88A0A7E42594 Q36712121-FAFF892A-D8BE-43BF-8C8B-6333A1217426 Q37090794-35EDCF5D-A3D3-40A8-A8FD-B56AC9311339 Q37373292-4BCAB181-DEA3-4B43-904E-CDE64B36E6FE Q37570615-88B83B99-8CA9-40E4-A8BC-E9F0A952C1B5 Q38131710-0A4F6D42-9DCF-4C09-BCB5-33EBAC70E25F Q38172295-F0DE2555-63A1-47F8-A519-2E01E2C1186A Q38259728-16297363-88E0-4C42-8092-867842D744B1 Q38275212-D32CC370-D53A-4570-8C30-13618A64B15B Q38362383-7F3E9B28-5CD9-4D20-AE12-2D9C54BD181A Q38370866-8127E6EF-E96D-4C41-B02A-4F6AED665405 Q38587648-DF4FBC8C-9F99-4E5C-879E-B33C3603C7D0 Q38613822-4880CE31-5870-4F13-9620-54EFC9AB7F32 Q38614967-CAD9C226-3FAC-4CF1-9C01-2CD08285B2B5 Q38779623-143DD1A8-FD96-4E36-8AA9-44FE8D9F6B0C Q38928383-A6EA27C2-23E0-485B-B760-78B69B790FDB Q39267653-59F9CFD7-8EBA-4A98-8A97-BA7F18C8A100 Q40036915-33F53808-BB02-4503-8729-54FEAC1A205F Q42958777-72118648-E7C5-44B1-95A2-C1DA862A9A38 Q43057972-9D223749-952C-4856-AF5A-9325FF30D177 Q43936667-49153FAD-2382-473C-8E71-E6FACC6B8959 Q44060632-DB385CCC-6892-477E-81B4-D497E9C37EFD Q46463218-8251E8DF-15FF-403C-B3A1-728284482628 Q46680983-0C9C52D8-6181-4E1D-8C39-4281F1577BCC Q47263519-426EDDC9-8B70-4C46-A422-80C9D40EE00A Q47428714-D9FC3404-7C52-4F2B-A430-DA4451E667A6 Q47561519-80A8F330-DE5C-43CA-8680-7EAB60EBA961 Q47643557-FC490248-17D2-40B6-BB47-11FBA7F837E5 Q50209795-85B6F2BA-EBF8-44E3-9FCA-791D7E571599 Q51786246-F9EC2365-95FA-45C1-8366-0C8B7AF30B94 Q52659305-49EBA56D-D9FC-40F2-A382-400EEACFDE6B Q55023498-7A85DAFB-5E46-4C0F-BD66-24C7976B629F Q55127439-201ACA2A-4B5B-4656-BA1C-EF77044B3BA8

P2860

Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis.

http://www.wikidata.org/entity/Q48382207

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Refinement in patient selectio ...... ransplantation in amyloidosis.

@en

Refinement in patient selectio ...... ransplantation in amyloidosis.

@nl

type

label

Refinement in patient selectio ...... ransplantation in amyloidosis.

@en

Refinement in patient selectio ...... ransplantation in amyloidosis.

@nl

prefLabel

Refinement in patient selectio ...... ransplantation in amyloidosis.

@en

Refinement in patient selectio ...... ransplantation in amyloidosis.

@nl

P1433

Q48382207-352D62EA-F2C3-408D-BEFE-8ECB9AFD3671

P1476

Q48382207-BD87FDB6-424F-423C-A316-D0B5A4BC7776

P2093

Q48382207-0CA72F8D-5867-4E91-82FE-F84F0D1EB059

Q48382207-17A0D8FC-F7BC-4172-82EC-9CA13EF80000

Q48382207-3FEC8C4B-8032-40DA-8963-4DB7E64B4778

Q48382207-A0749EEA-C4F5-44B4-8F7A-16EDE3A3E4D0

Q48382207-C56DE76C-950F-44FA-BA28-B62765B18FA5

Q48382207-CF3BFE72-EFDB-41FC-8298-2CDC47D60546

Q48382207-F4DD7542-890B-4219-B9A5-0DAA00FF3820

P2860

Q48382207-041B50C9-55D9-4241-A15F-3A3A02E40E0A

Q48382207-0450FD7C-5B46-4FA1-84A6-F0B04ED63D19

Q48382207-0B3649CF-7080-4FED-AA22-C37A79B808C8

Q48382207-1450B66D-1677-467A-BE24-C8EEABCA0408

Q48382207-306680B7-840D-4361-A3F8-85B081BEA170

Q48382207-352B4647-C703-41EF-BD22-22B7B5DEE381

Q48382207-54F9BC2E-F40C-4979-974B-27787834BF83

Q48382207-64C7F151-C719-409C-935F-A5D650CDC6E0

Q48382207-69FB4A1D-B106-4B7D-B66D-02AE6F27806B

Q48382207-7142DB10-91F6-400E-B6EB-775FF8B4B10B

P2888

Q48382207-41495C52-D789-48FE-9E0B-31F35B342084

P304

Q48382207-475C072F-E60C-4C5F-82AE-148346F53E55

P31

Q48382207-34FC54C4-D256-4C3B-94A9-5DBD3DF06E45

P356

Q48382207-F9DF2F60-957C-480D-9D38-23C684B9E9B6

P407

Q48382207-606DD36A-7448-4D1C-B212-2475A5AC0D95

P433

Q48382207-86882F24-C494-4326-AE18-25E8712824E8

P478

Q48382207-BFF1F0BA-4B39-4C4A-946D-1FDE75B0929D

P50

Q48382207-01DD421D-36E3-4A3D-9C91-9571E729DDE6

Q48382207-7E75DB02-0ACD-44F8-B846-9DB6B049FED3

P577

Q48382207-1A75E676-79D6-4259-8BC0-76447EFFB38C

P5875

Q48382207-AE3D1E4B-1A3D-4121-988F-FEFB7AFCB101

P698

Q48382207-C8A4AB06-D464-4F4C-A6A6-2A544748E5C6

P921

Q48382207-9CF28C02-E6E9-445C-9F94-59CE4AF0DA0E

P356

P1433

Bone Marrow Transplantation

P1476

Refinement in patient selectio ...... ransplantation in amyloidosis.

@en

P2093

D Dingli

http://www.w3.org/2001/XMLSchema#string

F K Buadi

http://www.w3.org/2001/XMLSchema#string

M A Gertz

http://www.w3.org/2001/XMLSchema#string

M Q Lacy

http://www.w3.org/2001/XMLSchema#string

S K Kumar

http://www.w3.org/2001/XMLSchema#string

S R Hayman

http://www.w3.org/2001/XMLSchema#string

W J Hogan

http://www.w3.org/2001/XMLSchema#string

P2860

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens.

Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy.

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.

Stem cell transplantation for the management of primary systemic amyloidosis.

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.

Pitfalls in the diagnosis of primary amyloidosis.

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

P2888

P304

557-561

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2012.170

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

Angela Dispenzieri

P577

2012-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260202578

http://www.w3.org/2001/XMLSchema#string

P698

22964596

http://www.w3.org/2001/XMLSchema#string

P921